GlassScriptPhysician profile
Brandi Manning
NPI 1881781623
$5,309.63
in general payments reported to CMS, 2019-2025
31 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,677 · 2022: $1,251 · 2023: $992 · 2024: $801 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.46 | 2021-2025 | |
| Lilly USA, LLC | $592.66 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $574.67 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $518.06 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $412.06 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.31 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.95 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $204.61 | 2021-2022 | |
| Pfizer INC. | $194.18 | 2021-2025 | |
| Exact Sciences Corporation | $141.53 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $123.04 | 2021-2023 | Verquvo, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $123.00 | 2022 | |
| Abbott Laboratories | $113.43 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.94 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $88.49 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $85.82 | 2021-2022 | |
| Esperion Therapeutics, INC. | $69.02 | 2021 | |
| Dexcom, INC. | $52.96 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $51.32 | 2021-2022 | |
| Daiichi Sankyo INC. | $45.02 | 2022-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $42.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $42.29 | 2021 | |
| Corcept Therapeutics | $34.38 | 2025 | Korlym |
| Amgen INC. | $25.69 | 2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $23.35 | 2023 | |
| Astellas Pharma US INC | $18.93 | 2021 | |
| Amarin Pharma, INC. | $18.75 | 2022 | |
| Evoke Pharma, INC. | $18.73 | 2025 | |
| Ironwood Pharmaceuticals, INC | $16.14 | 2023 | Linzess |
| Teva Pharmaceuticals USA, INC. | $13.43 | 2021 | |
| Genentech USA, INC. | $7.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.